Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide in Recurrent or Persistent Uterine Carcinosarcoma
NCT00025506Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2001
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide in uterine carcinosarcoma (UCS), sponsored by National Cancer Institute. Primary endpoints: Probability of Progression-free Survival (PFS) for at least 6 months and Frequency and Severity of Adverse Effects. Started Sep 2001; status: completed.
02
Drugs
thalidomide
03
Conditions
uterine carcinosarcoma (UCS)
Beyond the preview
Go deeper on NCT00025506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00025506.